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INTRODUCTION
Normal-tension glaucoma (NTG) is a progressive optic neuropathy 
similar to primary open-angle glaucoma (POAG); however, NTG does 
not present with intraocular pressure (IOP) outside the statistically 
normal range. It has been difficult to conceptualize the disease entity 
of NTG, even more so after the removal of IOP from the description 
of glaucomatous optic neuropathy (GON)(1,2) and after the understan-
ding of the influence of central corneal thickness (CCT) in IOP measu-
rements(3). Moreover, publications on the subject are ambiguous and 
it is almost impossible to compare them. 
Both glaucoma phenotypes have normal anterior chamber 
angles, peripapillary retinal nerve fiber layer (RNFL) thinning, GON, 
and corresponding visual field (VF) defects(4,5). Because of these simi-
larities, it has been postulated that NTG and high-pressure POAG 
represent a continuum of open-angle glaucomas and differ basically 
in the importance of IOP on the development and progression of 
the disease(5). Therefore, it is crucial to define glaucoma based on the 
characteristics of the optic nerve and not to use a single risk factor, 
IOP, to distinguish among the various conditions of GON(1).
However, several structural and functional differences support 
the fact that different mechanisms may have a stronger role in the 
pathogenesis of NTG versus high-pressure POAG. Also, a recent study 
reported genetic variants associated with different tendencies towards 
POAG with lower or higher IOP(6). Furthermore, clinical impression 
and anecdotal evidence suggest that NTG with mean IOP in the high 
teens (>15 mmHg), in which circadian fluctuation and CCT could 
lead to a possible misdiagnosis of an IOP ≤21 mmHg, would differ 
from NTG with mean IOP in the low teens (≤15 mmHg), with different 
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RESUMO
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pathogenesis and progression patterns, harder to achieve target IOP, 
and higher incidence of disc hemorrhages. Nonetheless, a recent 
report does not support this assumption and underscores low-teens 
NTG as an important entity(7).
The proportion of NTG varies depending on different population 
studies. In Asian epidemiological protocols, NTG constituted the 
majority of open-angle glaucomas (52%-92%), depending on the 
country and study methodology(8). Normal IOP was measured in 
57.1% cases of POAG in a South African study(9). In white popula-
tions, the proportion of NTG was lower than that observed in Asian 
and African populations. In studies conducted in the United States, 
Netherlands, and Italy, NTG presented proportions of 31.7%, 38.9%, 
and 30%, respectively(10-12). 
 The etiology of NTG is most likely multifactorial and still not well 
defined. Moreover, several alternative treatments based on this diffe-
rent pathogenesis have been discussed. The objective of this study 
was to review the mechanisms involved in the onset and progression 
of NTG and the efficacy of established and alternative therapies for 
NTG treatment. 
Pathogenesis
The pathogenesis of NTG is unclear, and perhaps the development 
of the disease is a consequence of a complex interaction of several 
systemic and ocular factors. Different studies have shown that the 
cardiovascular system and intracranial pressure may be involved in 
the main pathways of optic nerve damage. Nevertheless, the complex 
relationship between these mechanisms and glaucoma pro gression 
continues to be debated. 
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Nocturnal systemic hypotension
A systematic review and meta-analysis on the involvement of 
circadian variations in arterial blood pressure (BP) and GON was per-
formed, including information about high-pressure POAG and NTG 
patients. There was no difference in the mean systolic or diastolic 
diurnal and nocturnal BP between patients with or without progression 
of VF defects. Nocturnal dips greater than 10% of daily systolic or 
diastolic BP were a risk factor for progressive VF loss. However, the 
data published do not allow a differentiation between physiological 
dipping and over-dipping as a risk factor for glaucomatous optic 
neuropathy(13).
A prospective study including only NTG patients monitored the 
arterial BP every 30 min over a 48-h period for the baseline and at the 
6- and 12-month follow-up visits. Of 85 patients enrolled, 29% had 
VF progression, and a multivariate analysis showed that the duration 
and magnitude of decrease in nocturnal BP during sleep, particularly 
10 mmHg lower than daytime BP, predicted VF progression(14).
The correlation between a pronounced fall in BP during sleep and 
progressive glaucomatous damage can be explained by ischemic in-
sults to the optic nerve generated by low ocular perfusion. The ocular 
perfusion pressure (OPP) is an indirect measurement calculated with 
arterial BP and IOP. In NTG patients, significant dips in BP during sleep 
and OPP were the risk factors for the severe progression of VF dama-
ge(15). The fluctuation of mean OPP also correlated with VF damage 
progression. In a retrospective study, each 1-mm increase in mean 
OPP fluctuation was associated with a 27.2% greater chance of glau-
coma progression during a follow-up period of 73.1 ± 11.2 months(16).
Autonomic dysfunction
The circadian variations of BP are regulated by sympathetic neural 
activity. This system is responsible for the increase in heart rate, stroke 
volume, and vasoconstriction. A chronic imbalance of sympathetic 
and parasympathetic activity, with a predominance of the sympa-
thetic system, leads to arterial and cardiac remodeling, endothelial 
dysfunction, decrease in local blood flow, and increase in tissue 
oxygen demand(17). 
Patients with NTG present with sympathovagal balance of the 
auto nomic nervous system that has been shifted towards sympathetic 
activity(18,19). Patients with a low heart rate variability, which reflects 
autonomic dysfunction with sympathetic predominance, had a greater 
risk for central VF damage progression than patients with a high heart 
rate variability(20).
Primary vascular dysfunction or Flammer syndrome was also 
correlated with NTG. This syndrome was characterized by an insuffi-
cient or improper adaption of blood flow, despite the presence of 
anatomically healthy vessels and the absence of a causative disease, 
and results in a transiently incorrect blood supply for the tissue needs. 
The leading symptoms include cold hands and/or feet, low BP with 
pronounced fall at night, prolonged sleep onset time, shifted circa-
dian rhythm, and reduced feeling of thirst. This presentation is more 
common in women, slender subjects, and Asians(21-23).
Obstructive sleep apnea/hypopnea
Another cause of imbalance in ocular perfusion that may lead to 
GON is the obstructive sleep apnea/hypopnea syndrome(24). This syn-
drome is characterized by recurrent complete or partial upper airway 
obstruction during sleep. The obstructive respiratory disturbance 
may last up to 2 min, leading to severe hypoxia and hypercapnia. A 
higher prevalence of NTG was reported in a cohort of patients with 
obstructive sleep apnea/hypopnea syndrome. The severity of the 
disease was inversely correlated with RNFL thickness(25).
Blood rheology impairment
The deterioration of the optic nerve caused by oxygen inade-
quacy could also be provoked by a disturbance in the physical 
properties of blood flow. Other pathological conditions, such as myo-
cardial infarction(26), stroke(27), and diabetes mellitus with peripheral 
circulation disorders(28), were correlated with abnormal hemorheo-
logical proprieties. 
Patients with NTG showed several abnormal blood parameters 
compared with normal subjects. The first group presented with 
higher blood viscosity, erythrocyte aggregability, flow resistance of 
erythrocytes, and poor erythrocyte deformability. All of these para-
meters represent low blood oxygen transport efficiency and may 
result in hypoperfusion of the optic nerve(29,30).
intracranial Pressure
A mechanical theory was proposed for the development of NTG. 
The lamina cribrosa is a thin area of scleral tissue, which separates two 
pressurized compartments, the intraocular and orbital subarachnoid 
spaces. It was hypothesized that an elevated posteriorly-directed 
pressure differential contributes to optic nerve damage and produ-
ces a posterior displacement of the lamina cribrosa(31). Conversely, 
increa sed posterior pressure presented an anteriorly directed pressure 
vector, associated with intracranial hypertension, that could cause 
pa pilledema(32).
The cerebrospinal fluid pressure was significantly lower in the 
NTG (9.5 ± 2.2 mmHg) than in high-pressure POAG (11.7 ± 2.7 mmHg, 
P=0.013) and control group (12.9 ± 1.9 mmHg, P<0.001) eyes. The 
translamina cribrosa pressure difference (calculated as the difference 
of IOP minus cerebrospinal fluid pressure) was significantly higher in 
the high-pressure POAG (12.5 ± 4.1 mmHg) than in the NTG group 
(6.6 ± 3.6 mmHg, P<0.001) and control group (1.4 ± 1.7 mmHg, 
P<0.001) eyes. Moreover, the perimetric loss was positively correlated 
with the translamina cribrosa pressure difference in a multivariate 
analysis with both glaucoma groups(33), and a negative correlation 
was found between this pressure and the neuroretinal rim area(34).
A recent meta-analysis, which included the previously cited stu-
dies, concluded that intracranial pressure was significantly lower 
in patients with high-pressure POAG and NTG than in the control 
subjects. Moreover, compared with non-glaucoma patients, the trans-
lamina cribrosa pressure difference was almost two times higher 
in patients with NTG and five times higher in high-pressure POAG 
patients(35). 
clinical evaluation
Several conditions could affect the optic nerve head and compli-
cate the diagnosis of NTG. Ischemic optic and hereditary optic neu -
ropathies, demyelinating optic neuritis, multiple sclerosis, trauma, 
intraocular infections, and intraorbital or intracranial mass with com-
pressive effects on the optic nerve or chiasm have been reported to 
produce optic disc cupping and VF defects(36-39), and these diseases 
do not present with elevated IOP.
There is insufficient evidence to recommend a routine neurora-
diological evaluation in all NTG patients. However, young individuals 
with a significant decrease in visual acuity, vertically aligned VF 
defects, and neuroretinal rim pallor may present with anterior visual 
pathway compression caused by an intracranial mass, which should 
be evaluated with neuroimaging examinations(40,41). 
After eliminating all secondary causes of glaucoma and possible 
diseases that could lead to a misdiagnosis of NTG, it is important to 
evaluate the influence of CCT on IOP. A thin CCT underestimates the 
true IOP and can inaccurately classify a patient as having NTG(3,42,43). 
Nonetheless, the relationship of CCT and glaucomatous structural 
damage severity or NTG progression is controversial(44-46). 
Other corneal biomechanical properties may be related to optic 
nerve head damage in glaucoma. Hysteresis refers to the ability of the 
ocular connective tissues to dampen pressure changes. Eyes with a 
more deformable cornea, less viscous damping, and lower corneal 
hysteresis could have optic discs more susceptible to glaucoma damage 
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from increased IOP(47-49). Corneal hysteresis measurements were sig-
nificantly lower in patients with high-pressure POAG and NTG than 
in normal subjects(50). Also, a faster progression of VF damage in NTG 
patients with low corneal hysteresis has been observed(51). 
Vascular dysfunction in peripheral microcirculation was associa-
ted with central VF defects in NTG patients and could be evaluated 
by nail fold capillaroscopy(52). Other systemic evaluations could be 
helpful to NTG suspects. Ambulatory BP monitoring could be perfor-
med to detect a pronounced decrease in BP during sleep, and sleep 
polysomnography could be used to diagnose obstructive apnea/
hypopnea cases.
structural differences between ntg and Poag
Optic disc
Some differences exist in biomicroscopic features of optic nerve 
damage in NTG patients. The optic cups seem to be larger in patients 
with NTG than in those with high-pressure POAG. Moreover, the borders 
of the neuroretinal rims are not well defined and are saucerized and 
thinner, particularly in temporal and inferior zones(53,54). Disc analysis 
with Heidelberg retina tomography (HRT) showed larger optic discs 
with larger and deeper cups in patients with NTG than in those with 
high-pressure POAG(55,56). 
Macular ganglion cell complex
In NTG patients, macular ganglion cell complex thickness and 
peripapillary RNFL thickness showed a similar ability to discriminate 
glaucomatous from normal eyes(57).
Kim et al. compared the macular ganglion cell complex thickness 
of subjects with NTG and high-pressure POAG. For equivalent ave-
rage peripapillary RNFL defects (90.92 ± 16.00 and 84.00 ± 14.49, 
P=0.053) and VF mean deviation (MD; -7.09 ± 5.36 and -7.70 ± 4.40, 
P=0.746), the macular ganglion cell complex loss was more localized 
in the inferior hemifield in NTG patients and more diffused in the 
high-pressure POAG group(58).
Prelaminar tissue
Jung et al. investigated the difference in prelaminar tissue thickness 
between patients with high-pressure POAG and NTG using enhanced 
depth imaging optical coherence tomography (OCT). The prela-
minar tissue was significantly thinner in the high-pressure POAG 
group than in the NTG group, particularly in the early stages of the 
disease. The prelaminar thickness negatively correlated with IOP in 
both groups. Based on these results, they suggested that IOP was the 
main pathogenic factor in the nerve damage of patients with NTG 
and high-pressure POAG(59).
Lamina cribrosa
The lamina cribrosa is apparently influenced by factors other than 
IOP only. Park et al. observed that NTG patients had a lower lamina 
cribrosa thickness than patients with high-pressure POAG, even in 
the early stages of the disease. In addition, patients with NTG who 
presented with disc hemorrhages during follow-up had a thinner 
lamina cribrosa than those without hemorrhage(60).
Using enhanced depth imaging OCT, Kwun et al. investigated 
the lamina cribrosa thickness of patients with NTG who had unila-
teral VF defects. VF-affected eyes had a thinner lamina cribrosa than 
their corresponding eyes with a normal configuration. Although 
the normal corresponding eyes of NTG patients did not have any 
VF defects, glaucomatous optic nerve heads, or RNFL defects, their 
lamina cribrosa was thinner than that in normal control subject 
eyes(61). Recently, Omodaka et al. reached similar conclusions using 
swept-source OCT to obtain a three-dimensional evaluation of the 
lamina cribrosa(62).
Peripapillary scleral thickness
In a study using a swept source OCT, in which scleral thickness in 
glaucomatous and non-glaucomatous myopic patients was compa-
red, it was observed that the posterior sclera was significantly thinner 
in the inferior region of glaucomatous eyes with high myopia, and 
this was related to the degree of vertical tilt and torsion. This difference 
may be related to changes in the optic disc and/or susceptibility to 
glaucoma even with normal IOP and could contribute to glaucomatous 
changes in the corresponding region(63). 
Choroidal thickness
The choroidal supply to the papillary area could also be an etiolo-
gical factor in glaucoma, particularly in NTG. However, the evaluation 
of choroidal thickness and its association with glaucoma show con-
flicting results. A cross-sectional study and meta-analysis in a Chinese 
cohort suggested that there was no relationship between choroidal 
thickness in the macular region and primary open-angle glaucoma(64). 
Another study in an adult Chinese population, the Beijing Eye Study, 
also did not show an association between peripapillary choroidal 
thickness measurements and the presence of glaucoma(65). Zhang et 
al. did not identify a relationship between peripapillary and macular 
choroidal thickness and the markers of severity of glaucoma (MD and 
RNFL thickness)(66).
Using the enhanced depth imaging (EDI) OCT, Hirooka et al. 
obser ved a reduced choroidal thickness in the inferonasal, inferior, 
and inferotemporal regions in the NTG patients compared with that 
in normal subjects(67). Park et al. compared the macular and peripa-
pillary choroidal thickness of normal subjects and high-pressure 
POAG and NTG patients and found no significant differences in macular 
thickness among the groups. However, in their study, the average 
peripapillary choroidal thickness was significantly thinner in NTG 
(147.01 ± 35.31 μm) than in control (226.35 ± 39.52 μm, P<0.001) and 
high-pressure POAG (200.11 ± 32.16 μm, P<0.001) eyes. Significant 
differences in the peripapillary choroidal thickness were observed 
between high-pressure POAG and NTG eyes in early, moderate, and 
severe stages of glaucoma (P=0.017, P<0.001, and P<0.001, respecti-
vely), classified by the VF MD index(68). 
Furthermore, a possible association between glaucoma and re-
duced choroidal thickness has been reported, but it is not yet clear 
whether it is primary or secondary to glaucoma damage.
disc hemorrhage
Disc hemorrhage is an important risk factor for the onset and 
progression of GON(69-73), particularly in NTG. This finding is an isolated 
splinter-like or flame-shaped hemorrhage within or on the margin of 
the optic disc or in the peripapillary retina extending to the disc rim.
Although the pathogenesis of disc hemorrhage has not yet been 
completely elucidated, several risk factors were associated with its 
occurrence. A history of migraine, narrower neuroretinal rim width 
at the baseline, low mean arterial ocular perfusion pressure, and the 
use of systemic beta blockers were independent risk factors for the 
occurrence of disc hemorrhage in treated NTG patients(74).
The occurrence of an enlarged RNFL defect was more frequent 
in NTG patients who presented with disc hemorrhage, and the loca-
tion of the defect was in the same region as that of the disc hemor-
rhage(75). Using serial EDI-OCT, Lee et al. observed that deformation 
or disruption of the lamina cribrosa precedes the occurrence of disc 
hemorrhage. The comparison of post- and pre-disc hemorrhage 
images showed that alterations spatially correlated with the location 
of the disc hemorrhage(76).
visual field defects and Progression
Caprioli and Spaeth compared the VF defects of patients with 
NTG with different glaucoma phenotypes with elevated IOP (primary 
open-angle, pseudoexfoliative, and pigmentary glaucoma). In this 
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protocol, patients with NTG showed significantly deeper and clo-
ser-to-fixation scotomas. In addition, the involvement of fixation did 
not depend on the extent and depth of the VF defect(77).
Similarly, in another study, patients with NTG were compared 
to those with high-pressure POAG adjusted to the same level of 
structural damage to the optic nerve and peripapillary nerve fiber 
layer as detected by HRT. It was observed that patients with NTG 
had a higher percentage of abnormal points in the upper and lower 
central regions(78).
The 24-2 VF test pattern points are spaced every 6°, and only four 
points fall within the central 8°. This region comprises more than 
30% of the retinal ganglion cell area(79). Traynis et al. suggested that 
24-2 standard perimetry could miss defects detected on the 10-2 VF 
test, particularly in the early stages of RNFL damage(80). Therefore the 
10-2 strategy should be included in the evaluation of patients with 
scotomas within the central 10°.
Patients with NTG and superior hemifield defects had signifi-
cantly faster progression rates than patients with inferior hemifield 
defects, and the difference between the progression rates was more 
pronounced in the central and nasal zones(81). In initial VF defects, no 
differences in progression rates were observed among patients with 
central scotomas compared with those with peripheral defects(82).
A relationship between a preferred sleeping position and an 
asymmetric VF loss in NTG patients was reported. In this retrospective 
study, 66% of NTG patients with asymmetric VF loss presented a worse 
eye in their preferred lateral decubitus position(83). A compressive 
effect on the eye globe with an increase in IOP or a reduction in per-
fusion of the optic nerve could be possible mechanisms to explain 
these results. 
To study risk factors for the progression of the VF defect in pa-
tients with NTG, Lee et al. separated two groups according to IOP 
(above and below 15 mmHg). There was no difference in the pro-
gression rates between the two groups. In the group with pressure 
>15 mmHg, IOP was a risk factor for progression. However, in the 
group with lower pressures, the presence of optic disc hemorrhages 
was the only risk factor, demonstrating that progression mechanisms 
are not exclusively dependent on pressure values(84).
The risk factors for the progression of glaucomatous damage 
detected by the NTG Collaborative Study Group were female sex, 
mi graine, and occurrence of optic disc hemorrhage(85,86). Sakata et al., 
in a retrospective analysis of an NTG cohort treated with hypotensive 
eye drops, reported that the extension of myopia was a risk factor 
for VF damage progression and that this progression often occurred 
in the upper paracentral region(46). The influence of myopia on the 
progression rate of NTG was not observed by Sohn et al.(87). 
Despite different clinical features, epidemiology, and genetics, 
the glaucoma phenotype is not an independent risk factor for VF 
progression after covariate adjustment for all different subtypes in-
volved in the disease(88). 
treatment
The mainstream treatment for NTG is IOP reduction. The Colla-
borative Normal-Tension Glaucoma Study demonstrated that a 30% 
IOP reduction favorably influenced the progression of this disease 
in glaucoma patients compared with untreated NTG controls. The 
favorable effect of IOP reduction in the treated group was found 
only when the impact of cataracts on VF progression was removed. 
Moreover, in the same study, even after achieving the expected IOP 
reduction, the disease continued to progress in 12% of patients(89,90).
The most frequently prescribed antiglaucoma drugs used in mo-
no therapy in several studies did not reach the pressure reduction 
suggested by the Collaborative Normal-Tension Glaucoma Study. Pros-
taglandin analogues (latanoprost and bimatoprost), beta-blockers, 
and alpha-adrenergic agonists reduced the pressure from 16% to 
20% when used in monotherapy(91,92). Among fixed combinations of 
drugs, the dorzolamide-timolol compound reduced 23.7% of base-
line IOP, and combined brimonidine-timolol drops lowered IOP by 
3.8 mmHg (23%) after 12 weeks of use in NTG patients(93,94). 
The Low-pressure Glaucoma Treatment Study compared the 
effects of brimonidine and timolol in monotherapy for NTG. Brimoni-
dine-treated patients were less likely to have VF progression despite 
known comparable IOP decreases(95). Although these results should 
be interpreted carefully because of the high rates of discontinuation 
in the brimonidine group, the results suggested that brimonidine 
was relatively protective, possibly due to IOP-independent pathways. 
Hayreh et al. suggested that topical beta-blocker eye drops induce 
a significant drop in mean diastolic BP at night and that beta-blo-
cker-treated NTG patients showed VF damage progression more 
frequently than those not receiving this class of eye drops(96). 
The neuroprotective effects of brimonidine have been described 
in some pre-clinical studies. To avoid the brimonidine IOP effect, the 
drug was administered intraperitoneally in rats with episcleral vein 
cauterization-induced glaucoma. Treated animals showed a lower 
rate of retinal ganglion cell loss after IOP elevation(97). In an optic nerve 
crush model, Lindsey et al. observed a similar action of intraperitoneally 
administered brimonidine on RGC protection(98). 
Other drugs have shown neuroprotective benefits in experi-
mental glaucoma models. Memantine, an inhibitor of glutamate flux 
through the N-methyl-D-aspartate receptor, is clinically used in 
neu rological disorders, such as Alzheimer’s dementia.(99,100) Although 
several preclinical studies have demonstrated that memantine had a 
neuroprotective effect(101-103), a large randomized clinical trial failed to 
show the same effect in human glaucoma (data not published)(104). 
The Memantine Trial actually showed that the progression of disease 
was significantly lower in patients receiving the higher dose of me-
mantine than those receiving the low dose. However, there was no 
significant benefit compared to patients receiving placebo(105).
Extracts of Ginkgo biloba have been suggested for many years to 
treat various conditions, particularly circulatory problems, Alzheimer’s 
and other age-associated dementias, cerebral blood insufficiency, 
and schizophrenia(106). Several studies have been conducted to test its 
potential as a neuroprotective and antioxidative drug and to unders-
tand the possible benefits in the management of neurological and 
vascular conditions(107). 
There is no consensus on the effects of G. biloba in NTG patients. 
Quaranta et al. reported that its administration for 4 weeks improved 
the VF MD index in preexisting VF damage in some individuals with 
NTG(108). Lee et al. reported that a prolonged (72.1 ± 16.4 months) 
administration of G. biloba slowed the progression of VF damage 
in patients with NTG, particularly in the superior central region(109). 
In contrast, in a Chinese cohort in a randomized clinical trial with NTG 
patients, Guo et al. assessed the impact of G. biloba on preexisting 
VF defects and contrast sensitivity. In this study, no effects on VF and 
contrast sensitivity were observed after 4 weeks of use(110). 
Systematic reviews on the use of G. biloba as a treatment of inter-
mittent claudication(111), tinnitus(112), multiple sclerosis(113), age-related 
macular degeneration(114), and neurodegenerative progression of 
Alzheimer’s disease(115) do not suggest a clear clinically significant be-
nefit. More randomized clinical trials in different populations are ne-
cessary to verify the efficacy of G. biloba on NTG patients.
Furthermore, several drugs that act on ocular blood flow have 
been tested. Calcium channel blockers, such as nimodipine, normalized 
the retinal blood flow in NTG patients with vasospastic symptoms(116) 
and increased the blood and choroidal flow(117). However, its potential 
benefits must be validated in randomized clinical trials. Oral magne-
sium therapy seems to improve the VF MD index in NTG patients; 
however, there were no significant changes in ocular blood flow as 
seen in a prospective trial(118). 
Recently, it was demonstrated that salicylic acid/aspirin exhibits 
the ability to suppress the translocation of glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) to the nucleus and cell death. GAPDH 
is a cytosolic enzyme that has a central role in the production of 
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energy via glycolysis and participates in DNA repair and transcription; 
this is what makes it a major suspect in neurodegenerative diseases, 
including Alzheimer’s, Parkinson’s, and Huntington’s diseases. Therefore, 
salicylic acid/aspirin may have a potential role in the treatment of a 
wide variety of diseases, including glaucoma(119).
Laser and surgical treatment
Despite the low IOP after treatment, approximately 50% of 
patients with NTG had VF damage progression as detected by peri-
metry(120,121). It is possible that patients with this condition have a 
lower threshold for IOP mechanical injury than those with other glau-
coma phenotypes and that more substantial IOP reduction is often 
necessary compared with the one achieved with topical medications 
or trabeculoplasty.
Studies involving selective laser trabeculoplasty (SLT) and NTG 
showed that the average rate of reduction of IOP was 14.7%, correla-
ting with a reduction of 26.7% in the number of used drops. The suc-
cessful predictors of SLT were an elevated IOP before the procedure 
and a higher pressure drop in the first week after the procedure(122).
Most patients achieve the therapeutic target using antiglauco-
ma medications and laser trabeculoplasty. In eyes experiencing VF 
damage progression despite treatment and low IOP levels, a filtering 
surgery must be performed. The surgical approach in those patients 
presents a therapeutic challenge because of the need to achieve 
pressures of a single digit without occurrence of any hypotony-re-
lated complications. In a retrospective study, Iversen et al. and Schultz 
et al. reported that 90% of patients with NTG who underwent trabe-
culectomy achieved IOP of <10 mmHg at the 1-year follow-up, and 
the probability of success was 68% after 4 years. However, 53% of 
patients had postoperative complications, with hypotony being the 
most common(123,124). 
To avoid hypotony, Jayaram et al. performed a trabeculectomy 
with tight releasable sutures applied with the aim of observing no 
aqueous flow at the end of the procedure. Subconjunctival steroid, 
5-fluorouracil injections, or slit-lamp needling were performed when 
necessary. The authors obtained more than 30% of IOP reduction 
in 91.1% at 1 year of follow-up and 62.1% at 4 years. Early and late 
hypotony rates were 2.8% and 0.8%, respectively. 
Deep sclerectomy can be an option to trabeculectomy for 
pro gressive NTG patients. In this non-perforating technique, the 
intact inner trabecular meshwork offers sufficient resistance to flow 
avoiding severe hypotony. Suominen et al. performed a prospective 
comparison of patients who underwent deep sclerectomy with or 
without mitomycin-C (MMC) with a 12-month follow-up period. 
Both groups received a collagen implant under the scleral flap. Total 
success (more than 25% reduction of IOP) was achieved in 67% and 
41% of eyes in the MMC and non-MMC groups, respectively. One 
digit IOP, with or without medication, was more frequent in the 
MMC than in the non-MMC groups (47% vs. 9%, P=0.009). Hypotony 
was observed in 27% eyes of the MMC group at the early postope-
rative period. No eye in either group had hypotony at the 12-month 
postoperative visit(126).
CONCLUSION
The complex etiology of NTG is not yet completely understood; 
however, several studies presented differences between this disorder 
and high-pressure POAG. In clinical practice, the adequate reduction 
of IOP remains the keystone of managing NTG patients. Some alter-
native treatments must be tested further in randomized clinical trials 
to verify their therapeutic effects. 
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